Skip to Content
Merck
  • Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.

Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.

Science (New York, N.Y.) (1999-04-24)
Y H Kim, J H Park, S H Hong, J Y Koh
ABSTRACT

Human recombinant tissue plasminogen activator (tPA) may benefit ischemic stroke patients by dissolving clots. However, independent of thrombolysis, tPA may also have deleterious effects on neurons by promoting excitotoxicity. Zinc neurotoxicity has been shown to be an additional key mechanism in brain injuries. Hence, if tPA affects zinc neurotoxicity, this may provide additional insights into its effect on neuronal death. Independent of its proteolytic action, tPA markedly attenuated zinc-induced cell death in cortical culture, and, when injected into cerebrospinal fluid, also reduced kainate seizure-induced hippocampal neuronal death in adult rats.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Terephthalic acid, 98%